This is important stuff on my blog, bkoffman.blogspot.com, a strong argument to consider a clinical trial and an even stronger push to make sure it is ethically designed.
ASCO 2014: Dr. Susan O'Brien Outlines Open Tri... - CLL Support
ASCO 2014: Dr. Susan O'Brien Outlines Open Trials of Novel Agents and Equipoise in Trial Design for CLL
Written by
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
Read more about...
4 Replies
•
AussieNeilPartnerAdministrator
Plenty of good info in your latest blog Brian, supported by very useful reference links. And thanks for dropping the brackets around your blog link; it's a pleasant surprise not to have to edit your post .
Neil
PaulaSVolunteer
Thanks Brian, very interesting. And I have to ask - did you arrive in time for your rental car?
Paula
Not what you're looking for?
You may also like...
ASCO 2014: Dr. Susan O'Brien Reviews the 3 years follow-up Data on Ibrutinib in CLL
Friends,
I am stuck at the airport on my way to OSU waiting for my delayed flight, so I thought I...
Revisiting Richter transformation in the era of novel CLL agents
September 2021
A thorough review of where we are with the understanding and treatment of Richter's....
Dr. O'Brien on Trial Design, CT scans and the one and only place for FCR.
Friends,
Please check out my blog: http://bkoffman.blogspot.com to hear my last interview from...
ASCO 2016: Dr. Susan O’Brien where she discusses frontline data on Acalabrutinib in CLL
We are 8 weeks out from the 2016 annual meeting of the American Society of Hematology and realize...
Chemotherapy vs Ibrutinib for CLL Frontline Treatment - Dr Susan O'Brien. 12 to 24% of FCR patients effectively cured 6 years after FCR
Anyone interested in the pros and cons of chemotherapy vs non-chemotherapy treatment should watch...